Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

Market Cap	8.40B -45.2%
Revenue (ttm)	1.93B +5.2%
Net Income	309.27M -37.0%
EPS	0.98 -38.4%
Shares Out	316.05M
PE Ratio	27.19
Forward PE	n/a
Dividend	0.35 (1.32%)
Ex-Dividend Date	Jun 12, 2026

Volume	1,620,485
Open	26.46
Previous Close	26.39
Day's Range	25.98 - 26.68
52-Week Range	25.70 - 50.86
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 2,360
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2025, SHA:688076's revenue was 1.94 billion, an increase of 19.57% compared to the previous year's 1.62 billion. Earnings were 332.42 million, a decrease of -17.80%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error